NCT04616040Not yet recruiting
A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer
A Non-interventional Registration Study Evaluating the Usage of Camrelizumab in the Treatment of Unresectable Locally Advanced/Recurrent or Metastatic Chinese Patients With Esophageal Cancer
Source: ClinicalTrials.gov · Last updated 4 Nov 2020 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The trial is a multi-center, open, observational registration study, which aims to evaluate the safety and efficacy of Camrelizumab (anti-PD-1 antibody) in the treatment of Chinese patients with advanced esophageal cancer in the real world.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 1030 (estimated)
- First submitted
- 10 Oct 2020
- Start date
- 1 Dec 2020
- Primary completion date
- 1 Dec 2023
- Lead sponsor
- Peking University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT04616040
What you commit to
- Study type: Observational
- Planned participants: 1030
- From 1 Dec 2020 to the primary completion date, 1 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Other drug blinded clinical trials are currently underway;
Other
- Evidence suggests that the patient is pregnant or breastfeeding;
- Other situations that are not suitable for inclusion in this study.
Who the study is looking for
- Sign informed consent and voluntarily participate in this study.
- Unresectable locally advanced/recurring or distant metastatic esophageal cancer patients confirmed by histology or cytology (AJCC 8th edition);
- Unresectable locally advanced patients who are unable or unable to receive radical treatment (including radical radio chemotherapy or radical radiotherapy, etc.) may be considered for inclusion;
- Patients who progress or relapse after neoadjuvant or adjuvant therapy may also be considered for inclusion;
- Age ≥ 18 years old;
- The investigator determines that the patient can receive Camrelizumab as a single agent or combination therapy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Cancer Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.